医学
银屑病
代谢综合征
内科学
超重
前瞻性队列研究
腹部肥胖
队列
胃肠病学
肥胖
血脂谱
流行病学
队列研究
人口
胆固醇
免疫学
环境卫生
作者
Karine Paschoal Botelho,Maria Araci de Andrade Pontes,Carlos Ewerton Maia Rodrigues,Max Victor Carioca Freitas
出处
期刊:Metabolic Syndrome and Related Disorders
[Mary Ann Liebert]
日期:2020-01-13
卷期号:18 (3): 154-160
被引量:17
标识
DOI:10.1089/met.2019.0092
摘要
Background: Tumor necrosis factor (TNF) is an important inflammatory cytokine in the pathogenesis of psoriasis and metabolic syndrome (MS). Patients with psoriasis have higher rates of MS; therefore, some authors suggest an MS screening within this population. In addition, TNF inhibitor treatment often modifies the metabolic profiles of these patients. This study describes the epidemiological, clinical, and laboratory characteristics of patients with psoriasis undergoing anti-TNF treatment and evaluates whether anti-TNF treatments influence changes in their metabolic parameters. Methods: A prospective 6-month cohort study followed patients who underwent three consecutive consultations at 0, 3, and 6 months. The sample composed of 83 patients with psoriasis using anti-TNF. Results: The mean age and disease duration of the patients were 48 ± 11 and 16 ± 9 years, respectively. Most patients were men (61.5%). The prevalence of MS was 36%, and high rates of abdominal obesity (59%) and overweight (82%) were observed. Anti-TNF treatment significantly altered total cholesterol levels (195.5 ± 36.17 vs. 183.5 ± 41.23, P = 0.04) and low-density lipoprotein (LDL) cholesterol levels (128.5 ± 31.26 vs. 113 ± 36.31, P = 0.04). This study has some limitations, such as small sample size, brief follow-up period (6 months), patient recruitment from a tertiary-level referral center, and no control group. Conclusions: Patients with psoriasis have high rates of MS, overweight, and obesity, but anti-TNF treatment seems to improve the metabolic profile of these patients by decreasing their total and LDL cholesterol levels.
科研通智能强力驱动
Strongly Powered by AbleSci AI